Nature Reviews Drug Discovery

Twenty years of induced pluripotent stem cells

Asher Mullard Jun 01, 2026 pp. 414-415 10.1038/d41573-026-00084-8

Trends in the landscape of clinical trials of innovative drugs in China since 2015

Sen Liu, Cheng Li, Yusu Jian et al. Jun 01, 2026 pp. 412-413 10.1038/d41573-026-00081-x

A peptide-guided strategy for kinase activation

M. Teresa Villanueva Jun 01, 2026 pp. 421-421 10.1038/d41573-026-00080-y

Eli Lilly inks dual-payload ADCs deal

Asher Mullard Jun 01, 2026 pp. 410-410 10.1038/d41573-026-00079-5

First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions

Asher Mullard Jun 01, 2026 pp. 411-411 10.1038/d41573-026-00078-6

Novel opioid provides cleaner pain relief

Katie Kingwell Jun 01, 2026 pp. 418-418 10.1038/d41573-026-00067-9

Dual-vector gene therapy for hearing loss secures first FDA approval

Asher Mullard Jun 01, 2026 pp. 409-409 10.1038/d41573-026-00075-9

First-in-class HIV drug nabs approval

Asher Mullard Jun 01, 2026 pp. 410-410 10.1038/d41573-026-00076-8

AhR inhibition promotes axon regeneration

Sarah Crunkhorn Jun 01, 2026 pp. 422-422 10.1038/d41573-026-00072-y

Remodelling complex macrocycles

Sarah Crunkhorn Jun 01, 2026 pp. 422-422 10.1038/d41573-026-00070-0

Fast-acting covalent protein drugs

Sarah Crunkhorn Jun 01, 2026 pp. 422-422 10.1038/d41573-026-00071-z

IL-2-TGFβ co-agonist induces immune tolerance

Sarah Crunkhorn Jun 01, 2026 pp. 422-422 10.1038/d41573-026-00073-x

In vivo CAR T purchase spree continues with Lilly deal worth up to US$7 billion

Asher Mullard Jun 01, 2026 pp. 409-409 10.1038/d41573-026-00068-8

Inhibiting the integrated stress response restores cognition

Sarah Crunkhorn Jun 01, 2026 pp. 420-420 10.1038/d41573-026-00066-w

Cell surface SRC flags tumours

Alex Eccleston Jun 01, 2026 pp. 419-419 10.1038/d41573-026-00065-x

A renaissance in targeting the PI3K/AKT/mTOR pathway

Sarah E. Conduit, Neil Vasan, Jennifer R. Brown et al. Jun 01, 2026 pp. 469-493 10.1038/s41573-026-01388-5

Wearable technologies in clinical trials for drug development: trends and emerging opportunities

Zahi A. Fayad, Robert P. Hirten, Girish N. Nadkarni et al. Jun 01, 2026 pp. 448-468 10.1038/s41573-026-01403-9

Dose-finding and optimization in drug development for rare diseases

Robert N. Schuck, Ruo-Jing Li, Mia Williams et al. Jun 01, 2026 pp. 407-408 10.1038/d41573-026-00035-3

The therapeutic potential of orphan adhesion G-protein-coupled receptors

Jin-Peng Sun, Peng Xiao, Ines Liebscher Jun 01, 2026 pp. 423-447 10.1038/s41573-025-01371-6

The pancreatic cancer drug market

Pragati Tripathi, Laura Ramos García, Rachel M. Webster Jun 01, 2026 pp. 416-417 10.1038/d41573-026-00027-3